Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.45 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25987650 | 0.86 | HTR2A (0.50) | MPOHTR2AHTR1AHTR6MEN1 | |
| SCHEMBL31708192 | 0.80 | HTR1A (0.63) | MPOHTR2AHTR1AHTR6SLC6A4 | |
| SCHEMBL25029791 | 0.79 | MTNR1A (0.40) | MPOHTR2ASLC6A4MEN1KMT2A | |
| SCHEMBL25029889 | 0.75 | HTR2A (0.48) | MPOHTR2AHTR1AHTR6SLC6A2 | |
| SCHEMBL25029539 | 0.75 | MPO (0.33) | MPOHTR2A | |
| SCHEMBL25029861 | 0.75 | MPO (0.44) | MPOHTR2AHTR1AHTR6SLC6A4 | |
| SCHEMBL25029536 | 0.75 | MPO (0.33) | MPOHTR2A | |
| SCHEMBL25030273 | 0.73 | MPO (0.55) | MPOHTR2AHTR1AHTR6SLC6A4 | |
| SCHEMBL31708041 | 0.69 | MPO (0.57) | MPOHTR2ASLC6A4SLC6A2MEN1 | |
| SCHEMBL25030287 | 0.68 | HTR2A (0.76) | MPOHTR2AHTR1AHTR6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | Kuleon, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | Kuleon, LLC (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | Kuleon, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023018864-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780807-B2 | Benzoselenophene, benzothiophene, and benzofuran analogs and methods of modulating the serotonin 5-HT2C receptor | HTR2C, HTR2A, HTR3C | MPO 4717/4885HTR2A 2/4885HTR1A 8/4885 |
| US-20230257346-A1 | BENZOSELENOPHENE AND SELENOPHENOPYRIDINE ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTOR | HTR2C, HTR2A, HTR3B | MPO 3274/4885HTR2A 2/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.